<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4179">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280604</url>
  </required_header>
  <id_info>
    <org_study_id>KPGA-10KMani-01</org_study_id>
    <nct_id>NCT01280604</nct_id>
  </id_info>
  <brief_title>Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy</brief_title>
  <official_title>Effects of Fenofibrate 160mg to 54mg Conversion on Triglyceride Levels in Patients on Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this randomized trial is to measure the impact of converting
      patients on statin therapy from fenofibrate 160mg to 54mg per day compared to patients who
      continue fenofibrate 160mg per day for triglycerides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Study subjects receiving fenofibrate 54mg will maintain similar triglyceride
      levels as patients on 160mg of fenofibrate.

      The primary objective of this randomized trial is to measure the impact of converting
      patients on statin therapy from fenofibrate 160mg to 54mg per day compared to patients who
      continue fenofibrate 160mg per day for triglycerides. Secondary objectives include
      evaluating effect of the dosage change on low-density lipoprotein (LDL), HDL, alanine
      aminotransferase (ALT), aspartate aminotransferase (AST), and serum creatinine (SCr), and
      the potential cost savings associated with prescribing 54mg instead of 160mg. Electronic
      medical records will be used to identify subjects and gather data on demographics, comorbid
      conditions, and concomitant lipid lowering therapy. Subjects will be recruited for
      enrollment via telephone by the principal investigator (PI), co-principal investigators
      (Co-PIs), or provider referral after eligibility screening and approval from their primary
      care physician. Subjects must provide written informed consent and Health Insurance Privacy
      and Accountability Act (HIPAA) privacy rule authorization prior to participation in this
      study. Subjects will be randomized to either the intervention arm (conversion to 54mg of
      fenofibrate) or to the control arm (remain on 160mg of fenofibrate). Subjects in both study
      arms will have fasting lipid panels, ALT/AST, and SCr evaluated at baseline. All subjects
      will have repeat labs approximately 8 weeks after enrollment. All subjects will continue to
      receive standard care based on lipid values. The study period will begin approximately
      October 29, 2010 and run to June 30, 2011.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Triglyceride Levels</measure>
    <time_frame>6-10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Triglyceride levels will be assessed in study participants 6-10 weeks after entry into study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low-density Lipoprotein (LDL)</measure>
    <time_frame>6-10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>LDL levels will be assessed in study participants 6-10 weeks after entry into study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-density Lipoprotein,(HDL)</measure>
    <time_frame>6-10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>HDL levels will be assessed in study participants 6-10 weeks after entry into study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase(ALT)</measure>
    <time_frame>6-10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>ALT levels will be assessed in study participants 6-10 weeks after entry into study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST)</measure>
    <time_frame>6-10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>AST levels will be assessed in study participants 6-10 weeks after entry into study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine(SCr)</measure>
    <time_frame>6-10 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>SCr levels will be assessed in study participants 6-10 weeks after entry into study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Intervention 'Fenofibrate 54mg'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 'Fenofibrate 160mg'</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate 54mg</intervention_name>
    <description>Subjects will receive fenofibrate 54mg daily.</description>
    <arm_group_label>Intervention 'Fenofibrate 54mg'</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18 years of age or older

          -  Patients actively taking fenofibrate 160mg and statin therapy

          -  A fasting lipid panel within the past 9 months with most recent triglycerides levels
             less than 200mg/dL

          -  Primary care physician approves participation and fenofibrate conversion

        Exclusion Criteria:

          -  Impaired renal function defined as creatine clearance â‰¤ 50ml/min

          -  Current enrollment in other studies or clinical trials

          -  Previous fenofibrate 54mg use

          -  A history of pancreatitis or known previous triglyceride levels &gt;1000mg/dL

          -  Pregnancy

          -  Members with plan benefits that include a deductible for lab services at Kaiser
             Permanente
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kendra Manigault, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pharmacy Resident</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaiser Permanente of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 4, 2015</lastchanged_date>
  <firstreceived_date>January 19, 2011</firstreceived_date>
  <firstreceived_results_date>October 14, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention</title>
          <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Meeting All Inclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention</title>
          <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57.2" spread="8.67"/>
                <measurement group_id="B2" value="57.55" spread="9.26"/>
                <measurement group_id="B3" value="57.41" spread="8.36"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="54"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Triglyceride Levels</title>
        <description>Triglyceride levels will be assessed in study participants 6-10 weeks after entry into study.</description>
        <time_frame>6-10 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Triglyceride Levels</title>
            <description>Triglyceride levels will be assessed in study participants 6-10 weeks after entry into study.</description>
            <units>milligram/deciliter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Triglyceride Levels</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="135.5" spread="36.22"/>
                  <measurement group_id="O2" value="108.3" spread="37.41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-Up Triglyceride Levels</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="152.7" spread="42.61"/>
                  <measurement group_id="O2" value="109" spread="39.70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low-density Lipoprotein (LDL)</title>
        <description>LDL levels will be assessed in study participants 6-10 weeks after entry into study.</description>
        <time_frame>6-10 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Low-density Lipoprotein (LDL)</title>
            <description>LDL levels will be assessed in study participants 6-10 weeks after entry into study.</description>
            <units>milligram/deciliter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Low-density lipoprotein</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95.32" spread="21.32"/>
                  <measurement group_id="O2" value="83.29" spread="22.99"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Low-density lipoprotein</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84.42" spread="21.05"/>
                  <measurement group_id="O2" value="78.71" spread="21.93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-density Lipoprotein,(HDL)</title>
        <description>HDL levels will be assessed in study participants 6-10 weeks after entry into study.</description>
        <time_frame>6-10 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>High-density Lipoprotein,(HDL)</title>
            <description>HDL levels will be assessed in study participants 6-10 weeks after entry into study.</description>
            <units>milligram/deciliter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline High-density lipoprotein</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="41.88" spread="9.58"/>
                  <measurement group_id="O2" value="41.79" spread="14.24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up High-density lipoprotein</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43.21" spread="38.99"/>
                  <measurement group_id="O2" value="38.79" spread="33.61"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase(ALT)</title>
        <description>ALT levels will be assessed in study participants 6-10 weeks after entry into study.</description>
        <time_frame>6-10 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Alanine Aminotransferase(ALT)</title>
            <description>ALT levels will be assessed in study participants 6-10 weeks after entry into study.</description>
            <units>international units/liter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Alanine aminotransferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29.76" spread="26.20"/>
                  <measurement group_id="O2" value="30.66" spread="26.61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Alanine aminotransferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.38" spread="9.13"/>
                  <measurement group_id="O2" value="29.96" spread="11.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST)</title>
        <description>AST levels will be assessed in study participants 6-10 weeks after entry into study.</description>
        <time_frame>6-10 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Aspartate Aminotransferase (AST)</title>
            <description>AST levels will be assessed in study participants 6-10 weeks after entry into study.</description>
            <units>international units/liter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Aspartate Aminotransferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27.48" spread="6.14"/>
                  <measurement group_id="O2" value="27.59" spread="8.57"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Aspartate Aminotransferase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="25.5" spread="5.41"/>
                  <measurement group_id="O2" value="26.36" spread="6.49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Creatinine(SCr)</title>
        <description>SCr levels will be assessed in study participants 6-10 weeks after entry into study.</description>
        <time_frame>6-10 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24"/>
                  <measurement group_id="O2" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Serum Creatinine(SCr)</title>
            <description>SCr levels will be assessed in study participants 6-10 weeks after entry into study.</description>
            <units>milligram/deciliter</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline Serum Creatinine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9880" spread="0.2571"/>
                  <measurement group_id="O2" value="1.14" spread="0.24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Follow-up Serum Creatinine</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1" spread="0.23"/>
                  <measurement group_id="O2" value="1.13" spread="0.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Subjects in the dose reduction group will be converted from 160mg of fenofibrate to 54mg of fenofibrate daily for 6-8 weeks.
Fenofibrate 54mg: Subjects will receive fenofibrate 54mg daily.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Subjects in the control group will be remain on 160mg of fenofibrate daily for the duration of the study (6-8 weeks).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kendra Manigault, PharmD, BCPS, BCACP, CDE</name_or_title>
      <organization>Mercer University/ Kaiser Permanente</organization>
      <phone>678-547-6216</phone>
      <email>manigault_kr@mercer.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
